More on RVMD

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-49.6% Growth)
- Ratings (9.6 Score)

Upcoming Events

- Earnings (8/12/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Revolution Medicines (NQ:RVMD)
Delayed: 186.16 +6.98 (3.90%)
Prev. Close $179.18  
Open$176.87 
52 Wk High$ 
52 Wk Low$ 
Day High$186.66 
Day Low$176.00 
P/E N/A  
EPS$ 
Volume1,832,630 

Friends, Peers and Foes (?): MRK, ABBV, ERAS, EYPT, BBOT (more...)

Jul 10, 2026 09:10 AM Truist Securities Reiterates Buy Rating on Revolution (RVMD)
Jul 9, 2026 07:09 AM Revolution (RVMD) PT Raised to $235 at Guggenheim
Jul 7, 2026 09:24 AM EMA begins phased review of Revolution Medicines' daraxonrasib
Jul 7, 2026 09:24 AM European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
Jul 6, 2026 09:23 AM Revolution (RVMD) PT Raised to $220 at UBS
Jul 6, 2026 08:00 AM Revolution (RVMD) PT Raised to $215 at Mizuho
Jul 2, 2026 12:09 PM Revolution (RVMD) PT Raised to $181 at Wedbush
Jul 2, 2026 08:01 AM Revolution Medicines reports Phase 1/2 data for zoldonrasib in pancreatic cancer
Jul 2, 2026 08:00 AM Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 
Jul 1, 2026 06:25 PM Form 4 Revolution Medicines, For: Jun 29 Filed by: Patel Sushil
View All Articles

Entities mentioned with RVMD

View All Entities